



Prothena Corporation PLC is a late-stage clinical biotechnology company with expertise in **protein dysregulation**. Fueled by a deep scientific expertise built over decades of research, Prothena combines its expertise in protein dysregulation and rigorous scientific approach to develop therapeutic candidates with best-in-class potential. The pipeline of investigational therapeutics at Prothena has the potential to **change the course of devastating neurodegenerative and rare peripheral amyloid diseases, diseases which affect millions of people and their families worldwide.**



Our mission is to make a real impact for patients

By the numbers

120+
employees

35+
years leading protein
dysregulation science

7
pipeline
assets

Our Values

Selfless • Courageous • Imaginative • Joyful

Our pipeline

Prothena's pipeline includes both wholly owned and partnered programs for the potential treatment of Alzheimer's, Parkinson's and a number of other neurodegenerative diseases, as well as rare peripheral amyloid diseases AL amyloidosis and ATTR amyloidosis.



[VIEW FULL PIPELINE](#)

PRX012, a wholly owned program that targets A β (amyloid beta) for the potential treatment of Alzheimer's disease

PRX123, a wholly owned dual A β -tau vaccine for the potential prevention and treatment of Alzheimer's disease

Prasinezumab, a potential first in class treatment for Parkinson's disease in partnership with Roche

PRX005 and PRX019, for the potential treatment of Alzheimer's disease in partnership with Bristol Myers Squibb

Birtamimab, a wholly owned program for the potential treatment of AL amyloidosis

NNC6019/PRX004, for the potential treatment of ATTR amyloidosis in partnership with Novo Nordisk

Scientific legacy

Our legacy includes foundational discoveries in the understanding of Alzheimer's disease



1986
Athena Neurosciences
founded



1996
Athena acquired
by Élan



2012
Prothena spins-out from
Élan with a wholly-owned
drug discovery platform



For more information, please visit the Company's website at www.prothena.com and follow the Company on Twitter @ProthenaCorp and LinkedIn @ProthenaCorporationPLC.

Follow us

